Dr. Xiang Zhou 周翔
Chief Physician, Associate Professor
Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive interventional oncology, including vascular interventions, ablation, radioactive seed implantation, ultrasound diagnosis, and image-guided biopsy and drainage for various tumors. Combines interventional radiology with targeted and immunotherapy.
Dr. Zhou holds a medical doctorate and completed postdoctoral research in Germany and Switzerland. As Deputy Director of the Interventional Therapy Department at the Cancer Hospital, Chinese Academy of Medical Sciences, Dr. Zhou has nearly 20 years of clinical experience. Research includes publications in Radiology and multiple national invention patents.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Tumor Ablation Professional Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee, Chinese Society of Ultrasound in Medicine and Engineering
- Standing Committee Member, Ultrasound Therapy Professional Committee, Chinese Society of Ultrasound in Medicine and Engineering
Name order: in Chinese the family name comes first (Zhou Xiang). Papers usually list the name as Xiang Zhou or Zhou X.
Selected publications
50 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Hyperthermia, 2026 (senior author): Predictive value of genetic and morphological evaluation (GAME) score for outcomes after thermal ablation in patients with colorectal liver metastases. PubMed 42860716
- Cardiovasc Intervent Radiol, 2026 (senior author): Upfront Thermal Ablation versus Neoadjuvant Chemotherapy Followed by Ablation for Oligometastatic Colorectal Liver Metastases: A Propensity Score Matching Analysis. PubMed 41915050
- BMC Cancer, 2026 (senior author): Impact of time to ablation on survival outcomes in patients with colorectal liver metastases: an inverse probability-weighted cohort study. PubMed 42277707
- Int J Colorectal Dis, 2026 (senior author): An interpretable machine learning model based on MRI radiomics and GAME score for predicting early recurrence after thermal ablation in colorectal liver metastases. PubMed 41513849
- Int J Hyperthermia, 2025 (senior author): Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases. PubMed 39894452
- J Gastrointest Cancer, 2025 (senior author): Early Recurrence of Colorectal Liver Metastasis (Number ≤ 5 and Largest Diameter ≤ 3 cm) after Resection or Thermal Ablation: a Multi-center Study of Patterns, Safety, Survival and Risk Factors. PubMed 40072796
- J Hepatocell Carcinoma, 2025 (senior author): Prognostic Value of Changes in Combined Child-Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors. PubMed 40061165
- J Hepatocell Carcinoma, 2025 (senior author): The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors. PubMed 39877858
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion